Jose Eustasio Meca Lallana

Millan-Pascual J, Valero-Lopez G, Iniesta-Martinez F, Hellin-Gil MF, Jimenez-Veiga J, Lopez-Tovar IA, Morales-Ortiz A, Meca-Lallana JE. Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study. Neurol Ther. 2024 Feb;13(1):153-164. doi: 10.1007/s40120-023-00572-8. Epub 2023 Dec 14. PubMed PMID: 38097868; PubMed Central PMCID: PMC10787726.

AÑO: 2024; IF: 3.7

38097868

Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, Meca Lallana V, Arocas Casan V, Iniesta Martinez F, Olascoaga Urtaza J, Meca Lallana JE. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrleng.2018.12.021. Epub 2021 Feb 26. PubMed PMID: 35465911.

AÑO: 2022

35465911

Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Haring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. PubMed PMID: 34605319; PubMed Central PMCID: PMC9024029.

AÑO: 2022; IF: 5.8

34605319

Mutukula N, Man Z, Takahashi Y, Iniesta Martinez F, Morales M, Carreon-Guarnizo E, Hernandez Clares R, Garcia-Bernal D, Martinez Martinez L, Lajara J, Nuñez Delicado E, Meca Lallana JE, Izpisua Belmonte JC. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. Stem Cell Res. 2021 May;53:102319. doi: 10.1016/j.scr.2021.102319. Epub 2021 Apr 15. PubMed PMID: 33894548.

AÑO: 2021; IF: 1.587

33894548

Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. PubMed PMID: 34418400; PubMed Central PMCID: PMC8434816.

AÑO: 2021; IF: 59.935

34418400